WuXi Biologics Should See Expanding Pipeline and Backlog Despite Geopolitical Risk

WuXi Biologics should continue to maintain a leading market position in China as well as globally, given that over 60% of revenue comes from North America, where many of its clients are leading-edge pharmaceutical firms. WuXi has been investing heavily in manufacturing capacity to meet rising demand. The growing number of Chinese biotech companies has been a tailwind; they prefer a domestic champion, which should add to WuXi’s pipeline. Unlike big US companies, Chinese biotech startups often lack in-house manufacturing capabilities, leading to heavy reliance on external partners and the need for end-to-end development and manufacturing services. WuXi’s integrated platform, technology, and regulatory record provide Chinese biotech startups with services ranging from discovery to commercial manufacturing efficiently.